Back to Search
Start Over
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b
- Source :
- Value in Health Regional Issues; May 2014, Vol. 3 Issue: 1 p136-145, 10p
- Publication Year :
- 2014
-
Abstract
- Japan has one of the highest endemic rates of hepatitis C virus (HCV) infection. Treatments in Japan are currently limited to interferon-alfa–based regimens, which are associated with tolerability and efficacy issues. A novel regimen combining two oral HCV therapies, daclatasvir and asunaprevir (DCV + ASV), has shown favorable results in Japanese patients with chronic genotype 1b HCV infection. Comparisons of clinical and economic outcomes associated with DCV + ASV treatment and current standards of care were investigated.
Details
- Language :
- English
- ISSN :
- 22121099
- Volume :
- 3
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Value in Health Regional Issues
- Publication Type :
- Periodical
- Accession number :
- ejs33205683
- Full Text :
- https://doi.org/10.1016/j.vhri.2014.04.005